Calcineurin antagonists inhibit interferon-gamma production by downregulation of interleukin-18 in human mixed lymphocyte reactions. 2000

M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
Department of Surgery I, Okayama University Medical School, Japan.

Tacrolimus (FK-506) and cyclosporin A (CsA) are calcineurin antagonists used widely as T-cell immunosuppressants; however, their relative efficacy on the production of interleukin-18 (IL-18) remains undefined. We have examined the effects of FK-506 and CsA on the cytokine generation of human peripheral blood mononuclear cells (PBMCs) in mixed lymphocyte reaction (MLR) with lipopolysaccharide (LPS). We studied the levels of interleukin-18 (IL-18), IL-12, IL-10, IL-6, IL-2 and interferon-gamma (IFN-gamma) in the supernatant in allo-MLR by ELISA assay. Supernatant levels of IFN-gamma, IL-2, IL-6, IL-10 and IL-12 were detected 12 h after MLR and markedly increased thereafter. In contrast, production of IL-18 was detected at 12 h, reached a near maximum level at 24 h and decreased at 72 h. These results suggested that IFN-gamma production depended on IL-18, IL-12 and IL-2 in the early phase of MLR and depended mainly on IL-12 and IL-2 in the late phase. Both calcineurin antagonists inhibit the generation of IL-18, which plays a large role in allogeneic cell interactions, in macrophages and they also promote an equivalent down-regulation of T helper 1 (Th1) and Th2 responses in a concentration-dependent manner. About 90% of IFN-gamma production induced by MLR was inhibited by an anti-IL-18 antibody, showing that IL-18 can trigger IFN-gamma production in MLR. These results suggest that dual signaling consisting of antigen-driven nuclear factor of activated T cells (NFAT) activation and LPS-mediated NF-kappaB activation is crucial for IL-18 production in macrophages, and that IL-18 can trigger IFN-gamma production in T-cells by MLR.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D016559 Tacrolimus A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro. Anhydrous Tacrolimus,FK-506,FK506,FR-900506,Prograf,Prograft,Tacrolimus Anhydrous,Anhydrous, Tacrolimus,FK 506,FR 900506,FR900506,Tacrolimus, Anhydrous
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D020382 Interleukin-18 A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity. IFN-gamma-Inducing Factor,IL-18,Interferon-gamma-Inducing Factor,IFN-gamma Inducing Factor,IL18,Interferon-gamma Inducing Factor,IFN gamma Inducing Factor,Inducing Factor, IFN-gamma,Inducing Factor, Interferon-gamma,Interferon gamma Inducing Factor,Interleukin 18
D065095 Calcineurin Inhibitors Compounds that inhibit or block the PHOSPHATASE activity of CALCINEURIN. Calcineurin Inhibitor,Calcineurin Antagonists,Calcineurin Blockers,Protein Phosphatase 3 Inhibitors,Protein Phosphatase-2B Inhibitors,Inhibitor, Calcineurin,Protein Phosphatase 2B Inhibitors

Related Publications

M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
March 2007, American journal of reproductive immunology (New York, N.Y. : 1989),
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
September 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
February 1999, Inflammation,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
August 1986, Prostaglandins, leukotrienes, and medicine,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
August 1983, Immunobiology,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
December 1998, The Journal of infectious diseases,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
September 2002, Transplantation,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
November 1995, Human immunology,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
August 1981, Transplantation,
M Kuinose, and H Iwagaki, and Y Morimoto, and H Kohka, and K Kobashi, and H Sadamori, and M Inagaki, and N Urushihara, and T Yagi, and N Tanaka
November 2003, Clinical nephrology,
Copied contents to your clipboard!